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Autoimmune diseases include entities of varied clini-
cal expression such as juvenile onset diabetes mellitus, 
rheumatoid arthritis, multiple sclerosis, and thyroiditis. 
Nevertheless, these autoimmune diseases have a com-
mon origin; they are caused by clones of lymphocytes 
that specially attack the individual's own body compo-
nents. To study autoimmune processes, we have isolated 
and grown as long-term cell lines the T lymphocytes that 
mediate several different experimental autoimmune dis-
eases in rats or mice. These cell lines have increased our 
understanding of pathogenesis, but perhaps more im-
portantly, it appears that suitably attenuated lines can 
be used to immunize the individual animal against its 
own autoimmune cells. Thus, autoimmune cells can be 
used as vaccines to prevent or treat the autoimmune 
process. 
The object of t his article is to review salient findin gs in 
studies of an imal model s of autoimmune diseases in which we 
have used long-te rm cu ltured lines and clones ofT lymphocytes 
to study and manipulate the diseases. I shall introduce the 
disease mode ls, discuss their contribution to our understanding 
of pathogenesis and resistance to disease, and briefly comment 
on t he possible application of the new information to problems 
in human autoimmunity. 
Our use of autoimmune T cell lines to study autoimmune 
diseases is based on an idea of demonstrated usefulness in 
infectious diseases; pathogenesis and control of disease can be 
explored most easi ly when the etiologic agent is available for 
study and manipulation in pure cult ure. Autoimmune diseases 
patently differ from infectious diseases in that the etiologic 
agents are the individuals' own lymphocytes and not invading 
microbes. Nevertheless, we were attracted by the possibility 
that, simila r to pathogenic bacteria, autoimmune effector T 
lymphocytes might be grown in pure culture in vitro and used 
to advantage both to investigate how such cells cause disease 
and to develop new approaches to prevention or therapy by 
vaccination [1] . 
EXPERIMENTAL AUTOlMMUNE 
ENCEPHALOMYELITIS (EAE) 
EAE can be induced in a variety of species- rats, mice, guinea 
pigs, rabbits, dogs, monkeys, or humans- by immunization to 
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white matter of the central nervous system (CNS) in a suitable 
adjuvant such as complete Freund's adjuvant (CFA). The dis-
ease is characterized clinically by acute paralysis and histolog-
ically by mononuclear cell infiltrates a round blood vessels in 
the white matter of the CNS [2] . The critical antigen respon-
s ible for EAE is the basic protein of myelin (BP) (3]. It is 
interesting that different portions of the BP molecule are 
encephalitogenic for the various species. For example, the major 
encephalitogenic fragment of bovine BP for guinea pigs is a 
nonapeptide composed of residues 114- 122 of the molecule 
(4], while for rats the major encephalitogen is within the 68-
88 fragment of guinea pig BP [5]. Bovine BP is a relatively 
weak encephalitogen for rats and its encephalitogenic epitope 
is not in the 68-88 region [6] . 
EAE-induced using purified BP or fragments of BP is usually 
an acute monophasic disease and does not often manifest 
demyelination. Chronic or relapsing EAE with demyelination 
can be obtained in certain species by using particular proce-
dures of immunization with whole white matter rather than 
with BP (7]. Thus, the clinical manifestations of EAE can be 
influenced by the mixture of antigens and the mode of immu-
nization. Once rats or other animals recover from acute EAE, 
they acquire resistance to subsequent attempts to produce 
additional bouts of EAE by active immunization with BP [8]. 
EAE was the first autoimmune disease to be produced by 
lines of T lymphocytes. Ben-Nun and his associates developed 
T lymphocyte lines selected for their responses to BP and 
found that a single i.v. inoculation of such cells (105 -106 ) into 
naive syngeneic Lewis rats led to the clinical and histological 
les ions of EAE (9,10] . Instead of a latency period of 11 or 12 
days for expression of active EAE, the latency of disease 
induced by anti-BP line cells was inversely proportional to the 
number of line cells inoculated and could be as short as 2 days 
after a dose of around 107 cells. Similar to active EAE, EAE 
mediated by line cells was acute and most rats recovered 
spontaneously within 4-6 days. Only intact, activated anti-BP 
line cells induced EAE; cells treated by irradiation or mitomycin 
C, or cells specific for other antigens did not produce disease 
[11]. 
It was demonstrated that the anti-BP EAE effector line cells 
were not cytotoxic to BP-pulsed antigen presenting cells (APC) 
in vitro [12], although anti-BP cytotoxic T cells could be 
detected readily in immunized rats as they had in guinea pigs 
[13]. In addition to EAE, the line cells could also transfer to 
recipients' delayed hypersensitivity skin reactions to BP [12]. 
Therefore, the cells func t ioned as delayed hypersensitivity T 
lymphocytes, and showed the surface markers of helper or 
delayed hypersensitivity T lymphocytes [10]. Expression of 
EAE did not appear to require the recruitment of radiosensitive 
cells in the recipients as severe EAE developed in rats irradiated 
with 750 R. 
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EXPERIMENTAL AUTOIMMUNE THYROIDITIS 
(EAT) 
EAT, manifested by inflammatory cell infiltration of the 
thyroid gland is induced in mice by immunizing them with 
mouse thyroglobulin (Tg) in CFA [14] . Antibodies to Tg are 
produced by mice of almost all H -2 genotypes, but some H -2 
haplotypes such as H-2b express a low incidence of EAT (about 
July 1985 
20 %) while others such as H -2k express a high incidence (about 
80 %). Thus, H -2 high a nd low responder phenotypes relate to 
t he incidence of inf1ammation in the gland and not to the t iter 
of Tg a nt ibodies. Maron a nd Cohen mapped a critical EAT 
gene to H -2K [15]. 
Ruth Maron, Rachel Zerubavel , and their associates devel-
oped lines of mouse T lymphocytes [16] by priming mice with 
Tg/CFA and using Tg to select lymphocytes according to the 
method developed by Ben-Nun and Cohen [10] . A single int ra-
venous inoculation of a round 105 activated ant i-Tg line cells 
was suffic ient to induce EAT in na ive mice, irrad iated (550 R) 
mice, or t hymusless nude mice. Large numbers of line cells 
(about 106 ) produced disease in some recipients within 1 day 
a nd in a ll recipients wit hin 3 days of inoculation. The t hyroid-
itis was markedly more seve re t han t hat seen in active EAT 
and ran a subacute course, lasting for many weeks. EAT was 
mediated by line cells in the absence ofTg ant ibodies, providing 
confirmation of t he conclusion that T lymp hocytes una ided by 
ant ibodies could produce EAT [1 6]. 
ADJUVANT ARTHRITIS (AA) 
AA is a chron ic inflam mation of t he joints inducible in 
certain stra ins of rats that is similar pathologica lly to aspects 
of rheumatoid or other forms of immune arthritis in humans 
[17,18]. Unlike other models of experimenta l autoimmuni ty, 
AA is induced not by immunization to a defi ned self-a nt igen, 
but by immunization with CFA or with fractions of Mycobac-
terium tuberculosis (MT) organisms. AA was suspected to be 
an autoimmune disease because it cou ld be transferred to native 
rats by lymp hocytes from rats with AA [19]. Some workers 
suggested that collage n type II was the se lf-antigen target of 
immune attack in AA [20], while others have challenged t his 
notion [21 ]. 
Development of a rthri togenic lines ofT lymphocytes in AA 
was complicated by t he obscuri ty of t he putative autoa nt igen; 
t here was simply no self-antigen known t hat could be used to 
select t he relevant T lymphocytes in vitro. Joseph Holoshitz 
and his colleagues so lved this problem by using ground MT as 
the stimulating ant igen in ce ll cul ture. Although we did not 
know t he ident ify of the art hri togenic ant igen, we reasoned 
that the receptors of the ar thri togenic lymp hocytes t hemselves 
should recogni ze the cri t ical a nt igen from amo ng t he many 
irrelevant MT antige ns. Be t hat as it may, a rth ri toge nic lines 
ofT lymphocytes were generated using ground MT (22 j. 
Unlike the EAE and EAT lines t hat were capable of inducing 
disease in na ive recipients, t he arthri togenic lines produced 
disease only in irradiated rec ipient rats (750 R). Line-mediated 
AA required inoculation of about 2 x 107 line ce ll s, another 
marked difference from t he EAE and EAT models that were 
inducible with 100-fold fewer cells. The synovia of the join ts 
constitutes a la rge a rea for attack by the line cells compared to 
the focal ta rgets prov ided by t he CNS and thyroid and conse-
quently more line cells might be required to produce clinical 
arthri tis. In any case, the line cell s produced a subacute syn -
ovit is with t he hi sto logic picture of AA beginning 5- 7 days 
after inoculation and lasting up to 1 month. 
We are now using arthri togenic clones as tools to identify 
the critica l arthri togenic self-antigens in AA. The first line, A2, 
showed a small but significant degree of proliferative activity 
in vitro to co llagen type II , suggesting that collagen type II 
might be the ta rget of di sease [22]. However, we have now 
cloned the A2 line and have isolated a highl y arthri togenic 
subline, A2b that demonst rates no reactivity at all to coll agen 
type II [23]. Thus, it is unlikely that co ll agen type II is t he 
arthri togen ic target ant igen. Recent studies using t he A2b clone 
suggest that AA is caused by cross-reactivity between an a nti -
gen of MT and proteoglycans of join t cartilage (W. van Eden 
and J. Holoshi tz). Thus, relevant T lymphocyte clones can be 
raised without using purified ant igens and such clones can then 
be used to identify the critica l antigen. 
AUTOIMMUNE DISEASES AND T LYMPHOCYTE LINES 35s 
COVERT AUTOIMMUNITY 
The use of line technology to isolate and expand a limited 
number of T lymphocytes from the lymphoid organs of rats 
and mice has made it possible to define a carrier state of 
autoimmunity, t he presence of potential EAE effecto r T lym-
phocytes residing peacefully in the bodies of seemingly healt hy 
animals. We have raised anti-BP effector T lymphocytes from 
the thymuses of rats that had recovered from line mediated 
EAE (24] and from lymphoid organs of rats that had recovered 
from active EAE, or that had been inoculated with BP in 
incomplete Freund's adjuvant [8]. Moreover, genetically-resis-
tant PVG stra in rats were found to be capable of generating 
and were responsive to ant i-BP EAE effector T lymphocytes 
[25]. We had origi nally reported that EAE-resistant BN rats 
developed anti -BP T lymphocytes, but that these cells were not 
pathogenic (25]. However, we have now isolated pathogenic 
anti-BP T lymphocyte lines from BN rats. Thus, genetic re-
sistance to EAE is compatible with t he ge neration and carriage 
of covert autoimmune effector T lymphocytes. 
We have also succeeded in obtaining t hyroiditogenic lines of 
ant i-Tg-T lymp hocytes from H-2b stra ins of mice that are 
genetica lly resistant to EAT (unpublished data) . These show 
major histocompatibili ty complex (MHC) restriction in that 
they produce disease in low-responder H-2h mice but not in 
high-responder H- 2k mice. Thus, low responder mice possess 
thyroidi togenic T lymphocytes and t hese T lymp hocytes are 
restricted to low-responder H -2 products. 
The finding of autoimmune effector T lymphocytes in seem-
ingly healty animals implies the ex istence of contro l mecha-
nisms, amo ng them genetic, t hat regu late the express ion of 
these potent ially virulent cells. I shall return to the question of 
resistance to autoimmunity in t he section on vaccination. 
MIGRATION OF AUTOIMMUNE T CELLS IN VIVO 
The production of lesions by autoimmune T lymphocytes in 
spec ific organs requires t hat t he effector cells recognize the 
target organ as t hey ci rculate in the blood and lymph , exit from 
the vascular compartme nt, and atack t he organ in vivo. Exper-
iments were undertaken by Naparstek and others to investigate 
the homing of ant i-BP T lymphocyte line cells to the CNS and 
the biochemical machinery that might be used by T lympho-
cytes to penetrate blood vesse ls at t he site of antigen. We found 
that 5 1Cr-labeled anti-BP T lymphocytes were rapidly cleared 
from t he blood and the majo ri ty lodged in t he liver (85 %) and 
spleen (10%). One or two days before the onset of clinical EAE, 
about 2% of the injected cells were found in the CNS [11]. Line 
cell s of other ant igenic specificities were never found to accu-
mulate in the CNS, even during EAE. Thus, t he onset of cl inica l 
EAE was heralded by the accumulation in the CNS of a small 
fraction of the administered ant i-BP line cells. 
We were surprised to find that about 1% of anti-BP line cell s 
accumulated in t he thymus [24] . These autoimmune T cells 
were found to persist for months in the thym uses of rats that 
had spontaneously recovered from EAE, and could be isolated, 
cultured in vitro , and shown to induce disease in new recipients. 
In actively induced EAE, we could a lso detect ant i-BP effecto r 
T lymphocytes in the thymuses of recovered rats (8]. T hus, in 
addition to being a seat of cell differentiation , t he t hymus was 
found to be a repository of mature T lymphocytes returning 
from the periphery. 
Persistence of auto immune T cells in the thym us is another 
example of the carrier state of autoimmunity. Presumably, 
activation of persisting ce lls could be responsible for recurrent 
attacks of autoimmune disease. 
Homing of anti -BP T cells to the CNS implied that the cell s 
must have the means of recognizing the CNS when t hey course 
through it in the blood and penetrating the vessel wall to en ter 
the substance of the CNS. A candidate for such a mechanism 
is a specific enzyme, an endoglycosidase, t hat digests t he he -
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paran sulfate component of the vascular basement membrane. 
We found that activated effector T lymphocytes, similar to 
metastatic tumor ce lls, express such an enzyme in vitro [26] . 
Moreover, the presence of the BP antigen at the basement 
membrane led to a 5-fold increase in the enzyme. Thus, it is 
conceivable that BP leaking from the CNS can be recognized 
in the walls of the CNS blood vessels by anti-BP T lymphocytes 
and that thi s recognition induces expression of an enzyme 
needed by the T lymphocytes to penetrate into the target tissue 
[26]. 
PATHOGENIC MECHANISM OF DISEASE 
Once autoimmune T cells enter the target tissue, how do they 
cause damage? We have observed 2 different mechanisms that 
cou ld account for paralysis in EAE: by-stander inflammation 
and inhibition of nerve conduction. 
Bystander Inflammation 
lt was reported that inl1ammation of the CNS could be 
produced in animals with delayed hypersensitivity to purified 
protein derivate of MT (PPD) by injecting the PPD antigen 
into the CNS (27]. We have now confirmed and extended this 
using T cell lines spec ific for a variety of antigens. For example, 
anti-PPD line T cells introduced i.v. were induced into entering 
the CNS by inoculating rats intracerebrally with PPD [12]. 
Entry of the cells was associated with paralysis and EAE-Iike 
lesions. Arthritis or hepatiti s was produced by injecting the 
PPD antigen into the joints or liver, respectively. Similar 
findings were obtained with other foreign antigens and antigen-
specific line cells. Thus, int1ammation that was similar to 
autoimmunity could be induced using exogenous antigens in 
animals with T lymphocytes specific for the antigens. The T 
lymphocytes responsible for this bystander inflammation were 
delayed-type hypersensitivity cells [12]. 
Paralysis In Vitro 
As the clinical course of EAE cannot always be correlated 
with the presence or severity of cellular infiltrates in the CNS, 
we suspected that processes in addition to delayed hypersensi-
tivity reactions might play a role in the pathogenesis of EAE. 
Together with Yosef Yarom, an electrophysio logist, we tested 
the effects of line cells on nerve conduction in vitro [28] . We 
found that the presence of activated anti-BP T cells inhibited 
nerve conduction in syngeneic optic nerves, but not in synge-
neic peripheral nerves, or in a llogeneic optic nerves. Line cells 
recognizing antigens other than BP had no effect. Moreover, 
inhibition of nerve conduction was reversible and removing the 
anti -BP T lymp hocytes led to recovery of nerve function. 
Hence, anti-BP line cells seemed to exert an immunologically 
spec ific, but reversible, blockade of nerve conduction. The 
requirement for syngeneic optic nerve was compatible with 
assoc iative recognition of BP together with self-MHC at the 
level of the target nerve. 
VACCINATION AGAINST AUTOIMMUNITY 
The above findings suggested that the various line cells were 
etiologic agents of EAE, EAT, or AA. Taking a cue for infec-
t ious diseases, could these autoimmune T lymphocytes be used 
as agents for vaccination to induce resistance or treat disease 
without causing disease. 
EAE 
Anti-BP line cells were treated with irradiation or mitomycin 
C to attenuate their virulence and the cells were inoculated 
into syngeneic rats. We found that a single i.v. inoculation of 
about 106 or more attenuated line cells vaccinated about % of 
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recipients against active EAE [29]. We initially observed that 
vaccination was effective in preventing active EAE, but did not 
inhibit EAE mediated by anti-BP T lymphocyte lines [30]. 
However, we have now discovered that resistance to line me-
diated EAE may be obtained by repeated vaccination (unpub-
lished data) . 
Anti-BP lines that recognize different antigenic determi-
nants on the BP molecule could be used to vaccinate only 
against EAE induced by active immunization to that specific 
determinant [31] . Thus, the receptor specificity of the anti-BP 
line cells directed the fine specificity of the vaccination effect, 
a finding compatible with an antireceptor (anti-idiotypic) 
mechanism of vaccination. 
EAT 
A single inoculation of 3 X 106 irradiated anti -Tg cells vac-
cinated syngeneic mice, not only against active EAT induced 
by Tg/CF A, but also protected them from EAT mediated 
subsequently by passive transfer of the intact line cells [16]. 
Although protection against thyroid inflammation was com-
plete, the vaccinated mice produced high titers of Tg antibodies 
in response to active immunization. Thus, vaccination was 
selective in suppressing the EAT effector cells, but left un-
touched the Tg specific helper T cells and B lymphocytes 
needed for induction of antibody production. This selectivity 
could be explained by anti-idiotypic mechanism capable of 
distinguishing between effector and helper T lymphocytes that 
might interact with different antigenic determinants on Tg. 
AA 
We found that a single i.v. inoculation of A2 line cells 
protected all recipient rats against active AA induced by CF A 
from 2 weeks to at least 6 months later [22,23]. Because 
unirradiated recipients are refractory to line-mediated arthritis, 
we could induce vaccination in unirradiated rats using un-
treated line cells. 
A useful feature of active AA is its chronicity, lasting for 
weeks rather than days as does active EAE. We therefore were 
able to test whether A2 line cells, in addition to prevention, 
could be used to treat active AA after its clinical onset. Rats in 
which AA had been induced by CFA 16 days earlier, showed 
rapid regression of arthritis following administration of A2 line 
cells compared to controls (manuscript in preparation). Thus 
autoimmune T lymphocyte line cells can be used as therapeutic 
agents and not only as vaccines. 
Resistance to AA could be transferred from vaccinated rats 
using their thymus cells. This suggests that resistance induced 
by vaccination was immunological and probably involved T 
lymphocytes (J. Holoshitz, A. Matitiau, I. R. Cohen). 
Recently, we isolated a clone of line A2 that has no arthri-
togenicity, but administration of the intact clone to rats makes 
them resistant to subsequent atempts to induce AA. The clone 
could also be used to treat ongoing AA (unpublished data). The 
protective clone seems to recognize a different antigen than 
does the A2b effector clone (unpublished data). These findings 
suggest the possibility that the protective clone may work by 
inducing suppressor cells that inhibit the disease process. The 
protective clone, similar to the arthritogenic A2b clone, has the 
surface markers of helper T cells. Thus, the suppressor clone 
may be what is called a suppressor-inducer cell. 
These findings suggest that protection, in addition to an 
antireceptor or anti-idiotypic mechanism, may involve activa-
tion of suppressor cells. Thus, it is possible that more than one 
protective mechanism can be mediated or induced by T lym-
phocyte lines or clones. Be that as it may, it is clear that long-
term cultures of autoimmune T lymphocytes provide a new 
approach toward the control of autoimmune disease, at least in 
laboratory animals [1]. 
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PROSPECTS 
Human diseases thought to involve autoimmunity include 
multiple sclerosis, rheumatoid a nd simi lar types of arthri tis, 
insulin-dependent diabetes mellitus, t hyroidi t is, myasthenia 
gravis, systemic lupus erythematosus, and some skin diseases. 
Given our success in preventing or treati n g 3 experimental 
auto immune diseases, what a re t he prospects for clinical use of 
T lymphocyte line cells in human autoimmuni ty? 
It may be c la imed t hat clinical au to immuni ty differs funda -
menta lly from our experimental models in that t he clinical 
diseases are spon ta neous while t he experimenta l models we 
study are induced. Is t he re any reason to hope t hat processes 
effective in modifying a rtific ia lly induced autoimmunity could 
be effective in modifying sponta neous diseases in which p re-
meditated immunization plays no role? This is a weighty ques-
tion. However, t he term spontaneous may be merely a cover 
for our ignorance about t he factors t hat actua lly t rigger huma n 
auto immune diseases. We say a disease develops spontaneously 
when we don't understand how t he process is ini t iated. If 
disease is the outco me of a n interaction of t he individual with 
his or her environment, then factors in t he environmen t may 
be viewed as induce rs of t he disease. When t he critica l environ -
mental factors a re unknown , we say t he disease is spontaneous. 
Disease, s imila r to most biological happen ings, is the outcome 
of an interaction between a n individual genome and forces in 
the envi ronment . The te rm spontaneous places t he brunt of 
t he blame on t he genome while t he term induced incriminates 
the environment . Huma n and experimental models involve 
both t he genome and t he environment. The 3 experimental 
models we have studied- EAE, EAT, a nd AA- a re a ll influ-
enced greatly by ge nes within a nd without t he MHC. Not a ll 
rats and mice immunized with BP, Tg, or MT express disease. 
S imila rly , autoimmune disease is not an inev itable outcome of 
t he ge nome a lone. For example, about 50% of monozygotic 
twins escape developing insulin -dependent diabetes melli tus, 
even when t hey have grow n up in t he same house as have t heir 
genotypically identica l si blings who require insulin. Some en-
vironmen tal factor is needed to induce t he disease. Viewed from 
t his aspect, perhaps induced models of autoimmunity such as 
AA a re more fait hful to t he human condi tion t ha n a re t he more 
spontaneous models such as mouse lupus erythematosus which 
is inevitable in a lmost every mouse in a spec ia lly bred popula-
tion. Thus, there is n o reason to disqualify experimental models 
of disease merely because we know how t hey can be triggered. 
Some instances of autoimmunity in humans have been as-
sociated with microbial infection: Reiter's syndrome, acute 
rheumatic fever, a nkylosing spondyli tis , d iabetes, a nd rheu-
matoid a rt hri t is a re examples. Lines ofT lymphocytes derived 
from patients might be used, as we have done in AA, to uncover 
molecular mimic ry between microbia l a ntigens and t issue-spe-
cific epitopes [32]. Multiple scle rosis probably involves au toim-
munity to an unidentified component of CNS white matter. 
The isolation ofT ly mphocyte lines from patients could provide 
a way of characterizi ng t he critical target antigen. For example, 
we have found t hat lines ofT lymp hocytes from ra ts wi t h EAE 
regularly show spec ificity for t he major encepha li togenic frag-
ment of BP, even if we use crude white matter to select t he 
lines (unpubli s hed data). Thus, T lymp hocyte lines can be used 
to iden tify the immunologically dominant epitopes within a n 
undefined mixture of substances. 
Beyond diagnosis, could T lymphocyte lines or clones be used 
to manipulate disease? Obviously , treatment rather t han pre-
vention is the goa l. The value of t he anima l experiments derives 
from the obse rvation t hat t his goa l is feasible. H ow it can be 
done in huma ns and whether success will outweigh t he risks 
remains to be seen . The studies described he re provide an 
outline for beginning t he work. 
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